ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release first…
Author: Business Wire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors
NexThera vient de terminer le premier recrutement de patients dans le cadre d’un essai clinique aux États-Unis portant sur le NT-101, une goutte oculaire visant à traiter la DMLA humide
PUSAN, Corée du Sud–(BUSINESS WIRE)–NexThera Co., Ltd. (PDG : SaeGwang Park) a annoncé le 9 avril qu’elle avait terminé le premier recrutement des patients pour son essai clinique de phase 1/2a portant sur le NT-101, un nouveau traitement oculaire à …
Trends & Strategies Shaping the Cataract Surgery Devices Market, 2025-2033 – Phacoemulsification Systems and Femtosecond Lasers Driving Industry Growth – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Cataract Surgery Devices Market Size and Share Analysis – Growth Trends and Forecast Report 2025-2033” has been added to ResearchAndMarkets.com’s offering. The Cataract Surgery Devices Market is expected to reach US$ 12.47…
Tenpoint Therapeutics Ltd. Submits New Drug Application to U.S. FDA for BRIMOCHOL™ PF for the Treatment of Presbyopia
LONDON & SEATTLE–(BUSINESS WIRE)– #ophthalmology–Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that the…
7 Major Markets Stargardt Disease (STGD) Epidemiology Forecasts Report 2020-2024 & 2034: Focus on United States, EU4 (Germany, France, Italy, Spain), United Kingdom, and Japan – ResearchAndMarkets.com
DUBLIN–(BUSINESS WIRE)–The “Stargardt Disease (STGD) – Epidemiology Forecast – 2034” report has been added to ResearchAndMarkets.com’s offering. The report delivers an in-depth understanding of STGD, historical and forecasted epidemiology in the Unit…
GenSight Biologics met à disposition son Document d’Enregistrement Universel 2024
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN : FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurod…
GenSight Biologics Announces the Filing of its 2024 Universal Registration Document
PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and cent…
Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors
WALTHAM, Mass.–(BUSINESS WIRE)–Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of Jeff Ajer…
Alcon Publishes Agenda for 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2025 Annual General Meeting
Alcon Publishes Agenda for 2025 Annual General Meeting
GENEVA–(BUSINESS WIRE)–Alcon Publishes Agenda for 2025 Annual General Meeting
Aldeyra Therapeutics Receives Complete Response Letter from the U.S. Food and Drug Administration for the Reproxalap New Drug Application for the Treatment of Signs and Symptoms of Dry Eye Disease
LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced receipt…
ZEISS Vision Care Launches DuraVision® Gold UV AR, The New Gold Standard in Lens Coatings
HEBRON, Ky.–(BUSINESS WIRE)–ZEISS Vision Care, one of the world’s leading manufacturers of eyeglass lenses and ophthalmic instruments, announced today the launch of ZEISS DuraVision Gold UV AR, the latest high-clarity, anti-reflective lens coating in…
Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
GENEVA–(BUSINESS WIRE)–Alcon Expands Leadership in IOL Innovation with Clareon PanOptix Pro, Delivering Best-in-Class Light Utilization and Less Light Scatter
McKesson Corporation Completes Acquisition of PRISM Vision Holdings, LLC
IRVING, Texas–(BUSINESS WIRE)–McKesson Corporation (NYSE: MCK) today announced the completion of its previously announced acquisition of a controlling interest in PRISM Vision Holdings, LLC, a leading provider of general ophthalmology and retina mana…
Sydnexis Announces Positive CHMP Opinion in Europe for SYD-101 for Slowing the Progression of Pediatric Myopia
DEL MAR, Calif.–(BUSINESS WIRE)–Sydnexis, Inc. (www.sydnexis.com), a pre-commercial stage biopharmaceutical company, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has granted a positi…
Pennsylvania Employees Benefit Trust Fund (PEBTF) Announces Medical Plan Choices for 2026 for Commonwealth of Pennsylvania Employees Enrolled in the PEBTF
HARRISBURG, Pa.–(BUSINESS WIRE)–The Pennsylvania Employees Benefit Trust Fund (PEBTF) announced today that Aetna, a CVS Health company, has been selected to provide medical benefits to approximately 68,000 eligible Commonwealth employees and their de…
Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Aviceda Therapeutics Appoints Industry Veteran Dr. Jeffrey Nau as Chief Executive Officer to Lead Next Phase of Growth and Innovation
Nexus Pharmaceuticals Launches Fluorescein 2 mL
LINCOLNSHIRE, Ill.–(BUSINESS WIRE)–Nexus Pharmaceuticals, LLC is expanding their Fluorescein dosage options to include Fluorescein Injection, USP 25% in a 2 mL vial alongside Fluorescein Injection, USP 10% in a 5 mL vial. Nexus is committed to enhanc…
Tenpoint Therapeutics Ltd. to Participate in Upcoming Investor Conferences in April
LONDON & SEATTLE–(BUSINESS WIRE)– #ophthalmology–Tenpoint Therapeutics Ltd. to Participate in the RBC Capital Markets Virtual Ophthalmology and 24th Annual Needham Virtual Healthcare Conferences